News
Another Massachusetts biotech has reached the end of the road. | Another Massachusetts biotech has reached the end of the ...
IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...
Young inflammatory disease biotech Expedition Therapeutics is paying $17 million cash for licensing rights to an ...
Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...
Shortly after obtaining a green light from the FDA, SetPoint Medical announced $140 million in new funding to juice the commercialization of its neuromodulation implant for rheumatoid art | Shortly ...
As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...
The deal, which was signed in April 2024, saw Ipsen agree to hand over $75 million in a combination of upfront payment and ...
Bicycle Therapeutics is reducing its headcount by around 25% to extend its cash runway into 2028. | Bicycle Therapeutics is ...
Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...
When you think of biotech hubs, the first image that comes to mind may be the sleek waterfront offices of Boston Seaport or ...
A group of more than a dozen investors have together purchased a majority stake in HistoSonics, following reports earlier ...
Longevity company Altos Labs has secured a new clinical leader from the eye of the storm. Former Tornado Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results